AI that sees more
AI-powered solutions delivering smarter eyecare and deeper health insights
At Cascader, we harness the power of artificial intelligence to help clinicians — in hospitals and in primary care — optimise workflows and deliver better patient care.
Our mission is to use AI to enable safe, evidence-based decisions in high-volume, high-risk eye conditions, preventing avoidable sight loss, and to harness oculomics for non-invasive, early detection of systemic diseases — driving a shift toward preventative healthcare.
Our Roadmap
We’d like to share a glimpse of our current developments
— and how we see Cascader enhancing healthcare in the months ahead.
Cascader Launch
Moorfields Eye Hospital NHS Foundation Trust, the UCL Institute of Ophthalmology (IoO), and Topcon Healthcare announced in May 2025 the launch of Cascader Ltd, a new medical technology company that aims to transform the detection and management of eye disease through artificial intelligence (AI).
Cascader also builds on the growing field of Oculomics – the use of advanced retinal imaging to uncover insights into systemic conditions such as cardiovascular disease, neurodegeneration, and dementia.
Clinical Evidence
Our AI is evidence-led—built on extensive peer-reviewed research and rigorous clinical validation to prioritise patient safety and measurable clinical outcomes. See our trial summaries and linked publications…
Validation and Clinical Applicability of Whole-Volume Automated Segmentation of Optical Coherence Tomography in Retinal Disease Using Deep Learning
JAMA Ophthalmol.ogy 2021
Clinically Applicable Deep Learning for Diagnosis and Referral in Retinal Disease
Nature Medicine 2018
Dual site external validation of artificial intelligence-enabled treatment monitoring for neovascular age-related macular degeneration in England
Eye 2025